NervGen Pharma (NASDAQ:NGEN) Receives $18.00 Average Price Target from Analysts

NervGen Pharma (NASDAQ:NGEN) has earned an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

A number of equities analysts have recently commented on the stock. HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded NervGen Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 29th. TD Cowen started coverage on NervGen Pharma in a research report on Thursday, June 11th. They issued a “buy” rating for the company. Finally, Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd.

NervGen Pharma Stock Performance

NASDAQ:NGEN opened at $1.88 on Monday. The company has a market capitalization of $151.59 million and a P/E ratio of -20.89. NervGen Pharma has a twelve month low of $1.70 and a twelve month high of $6.30. The stock’s fifty day simple moving average is $2.48.

NervGen Pharma (NASDAQ:NGEN) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.